Morning Briefing
Summaries of health policy coverage from major news organizations
Global Funding Would Need To Triple To $9 Billion To Make Real Progress Against HIV, Malaria, Tuberculosis
The New York Times: Vaccines Against H.I.V., Malaria And Tuberculosis Unlikely, Study Says
Vaccines against H.I.V., malaria and tuberculosis — three major killers of the world’s poor — are unlikely to be produced in the foreseeable future unless vastly more money is committed to finding them, a new study has concluded. Other worthy goals that appear out of reach for now include a hepatitis C vaccine, a combination vaccine against the four leading causes of deadly diarrhea, a rapid cure for people who have caught tuberculosis and new treatments for a dozen neglected diseases, such as leprosy, dengue fever and sleeping sickness. (McNeil, 9/7)
Reuters: Ebola Fight Has New Science But Faces Old Hurdles In Restive Congo
When Esperance Nzavaki heard she was cured of Ebola after three weeks of cutting-edge care at a medical center in eastern Democratic Republic of Congo, she raised her arms to the sky with joy and praised the Lord. Her recovery is testament to the effectiveness of a new treatment, which isolates patients in futuristic cube-shaped mobile units with transparent walls and gloved access, so health workers no longer need to don cumbersome protective gear. (9/10)
The Associated Press: In Congo, A New And Less Isolating Ebola Treatment Center
Two times a day, Kasereka Mulanda comes to a new kind of Ebola treatment center to visit his wife, easing the isolation of a highly contagious disease. Stepping to the clear plastic sheeting around the cubicle where his wife is staying, he can speak with her without the need for a protective suit. In a part of Congo that faces a deadly Ebola outbreak for the first time, the contact is reassuring. (9/10)
